Brokerages Set Ardent Health, Inc. (NYSE:ARDT) PT at $14.67

Ardent Health, Inc. (NYSE:ARDT) has been assigned an average rating of “Hold” from the twelve analysts that are presently covering the firm, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation, four have issued a hold recommendation and six have given a buy recommendation to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $14.5833.

ARDT has been the subject of several research reports. Bank of America lowered their target price on Ardent Health from $12.00 to $10.00 and set an “underperform” rating for the company in a research note on Thursday, November 13th. KeyCorp cut shares of Ardent Health from an “overweight” rating to a “sector weight” rating in a research note on Monday, November 17th. UBS Group dropped their target price on shares of Ardent Health from $14.50 to $14.00 and set a “buy” rating for the company in a research report on Thursday, December 18th. Weiss Ratings restated a “sell (d)” rating on shares of Ardent Health in a research report on Monday, December 29th. Finally, Royal Bank Of Canada decreased their price objective on Ardent Health from $21.00 to $16.00 and set an “outperform” rating for the company in a research note on Friday, November 14th.

Ardent Health Stock Up 2.4%

NYSE ARDT opened at $8.50 on Monday. Ardent Health has a 1-year low of $8.22 and a 1-year high of $15.65. The company has a market capitalization of $1.22 billion, a price-to-earnings ratio of 5.86, a PEG ratio of 4.81 and a beta of 0.72. The stock’s 50 day moving average is $8.85 and its two-hundred day moving average is $11.63. The company has a current ratio of 2.08, a quick ratio of 1.95 and a debt-to-equity ratio of 0.67.

Ardent Health (NYSE:ARDT) last issued its quarterly earnings data on Wednesday, November 12th. The company reported $0.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.42 by $0.10. The company had revenue of $1.58 billion during the quarter, compared to analysts’ expectations of $1.55 billion. Ardent Health had a return on equity of 19.02% and a net margin of 3.24%.Ardent Health has set its FY 2025 guidance at 0.850-1.030 EPS. Equities analysts forecast that Ardent Health will post 1.23 earnings per share for the current fiscal year.

Institutional Trading of Ardent Health

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Oliver Luxxe Assets LLC raised its position in shares of Ardent Health by 1.5% in the 2nd quarter. Oliver Luxxe Assets LLC now owns 87,639 shares of the company’s stock valued at $1,197,000 after acquiring an additional 1,319 shares during the period. Geode Capital Management LLC increased its stake in Ardent Health by 0.6% in the second quarter. Geode Capital Management LLC now owns 286,848 shares of the company’s stock valued at $3,918,000 after purchasing an additional 1,769 shares in the last quarter. CWM LLC raised its holdings in Ardent Health by 990.6% in the second quarter. CWM LLC now owns 2,203 shares of the company’s stock worth $30,000 after purchasing an additional 2,001 shares during the period. The Manufacturers Life Insurance Company raised its holdings in Ardent Health by 8.3% in the second quarter. The Manufacturers Life Insurance Company now owns 27,530 shares of the company’s stock worth $376,000 after purchasing an additional 2,110 shares during the period. Finally, Strs Ohio boosted its position in shares of Ardent Health by 6.3% during the third quarter. Strs Ohio now owns 42,400 shares of the company’s stock worth $562,000 after purchasing an additional 2,500 shares in the last quarter.

Ardent Health News Summary

Here are the key news stories impacting Ardent Health this week:

• Positive Sentiment: Contrarian/bull case published outlining reasons to buy ARDT amid the selloff; may attract value investors looking past near‑term litigation risk. A Bull Case Theory
• Negative Sentiment: Multiple national plaintiff law firms have filed or issued investor alerts about a securities class action alleging accounting/revenue recognition and reserve misstatements tied to Ardent’s Q3 2025 results; firms are soliciting lead‑plaintiff applicants with a March 9, 2026 deadline — this increases the risk of litigation expense, management distraction, and prolonged share‑price pressure. Hagens Berman notice
• Negative Sentiment: Numerous additional firms (Kirby McInerney, Rosen, Bragar Eagel & Squire, Glancy Prongay & Murray, Schall, Kahn Swick & Foti, Pomerantz, Wolf Haldenstein, Levi & Korsinsky, BFA Law, etc.) have issued investor reminders or filed claims — amplifying media coverage and potential claimant interest, which can prolong uncertainty and downside risk for ARDT. Example notice: GlobeNewswire reminder
• Negative Sentiment: JPMorgan lowered its price target on ARDT from $12 to $11 and maintains a neutral rating — the cut signals reduced near‑term analyst confidence and may limit buying from institutional investors that follow bank research. Benzinga analyst note

About Ardent Health

Ardent Health, listed on the New York Stock Exchange under the ticker ARDT, is a healthcare delivery company focused on acquiring, developing and managing acute care hospitals and complementary outpatient facilities across the United States. The company’s integrated platform encompasses both inpatient and outpatient services, designed to provide end-to-end care solutions and address the full continuum of patient needs.

Through its network, Ardent Health operates general hospitals, emergency departments, ambulatory surgery centers, urgent care clinics, rehabilitation and post-acute care facilities.